BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCDA BioCardia

Post-Market Trading 09-27 18:38:54 EDT

2.94

+0.18

+6.52%

盘后2.96

+0.02+0.68%

18:22 EDT

High2.97	Low2.75	Vol140.98K
Open2.80	D1 Closing2.76	Amplitude7.97%
Mkt Cap10.30M	Tradable Cap6.78M	Total Shares3.50M
T/O408.60K	T/O Rate6.12%	Tradable Shares2.31M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"BCDA","market":"US","secType":"STK","nameCN":"BioCardia","latestPrice":2.94,"timestamp":1727467200000,"preClose":2.76,"halted":0,"volume":140979,"hourTrading":{"tag":"盘后","latestPrice":2.96,"preClose":2.94,"latestTime":"18:22 EDT","volume":756,"amount":2219.6869128,"timestamp":1727475739124},"delay":0,"floatShares":2305200,"shares":3501866,"eps":-5.269979,"marketStatus":"Post-Market Trading","change":0.18,"latestTime":"09-27 18:38:54 EDT","open":2.8,"high":2.97,"low":2.75,"amount":408596.2636725,"amplitude":0.07971,"askPrice":2.96,"askSize":760,"bidPrice":2.87,"bidSize":34,"shortable":3,"etf":0,"ttmEps":-5.269979,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1727481600000},"marketStatusCode":4,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":2.76,"preHourTrading":{"tag":"盘前","latestPrice":2.7708,"preClose":2.76,"latestTime":"09:29 EDT","volume":306,"amount":840.182976,"timestamp":1727443750447},"postHourTrading":{"tag":"盘后","latestPrice":2.96,"preClose":2.94,"latestTime":"18:22 EDT","volume":756,"amount":2219.6869128,"timestamp":1727475739124},"volumeRatio":0.636674,"impliedVol":0.8044,"impliedVolPercentile":0.4561},"requestUrl":"/m/hq/s/BCDA","defaultTab":"news","newsList":[{"id":"2468587618","title":"BioCardia Regains Compliance with Nasdaq Listing Rules for Minimum Equity Levels","url":"https://stock-news.laohu8.com/highlight/detail?id=2468587618","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468587618?lang=en_us&edition=fundamental","pubTime":"2024-09-18 22:22","pubTimestamp":1726669363,"startTime":"0","endTime":"0","summary":"BioCardia  said Wednesday it has fully regained compliance with Nasdaq's listing requirements to maintain shareholder equity of at least $2.5 million or a market capitalization of at least $35 million.The company said it received formal notice from Nasdaq that the company complies with the stock exchange's equity requirements and that it considers the matter closed.BioCardia said the Nasdaq notice follows several actions intended to shore up its balance sheet, including an upsized $7.2 million public offering of stock.Shares of the company rose more than 2% in recent trading activity.Price: 2.87, Change: +0.08, Percent Change: +2.69","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2210150020.SGD","LU2210149790.SGD","IE00B3QW5Z07.USD","BCDA","IE00BGHQF748.EUR","EQR","BK4112","BK4588","IE00B64PRP62.GBP","SQQQ","NQmain","LU2095319765.USD","NDAQ",".IXIC","QLD","QID","TQQQ","MNQmain","BK4585","BK4139","PSQ","BK4215","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2468581374","title":"BRIEF-Biocardia Regains Full Compliance With Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2468581374","media":"Reuters","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468581374?lang=en_us&edition=fundamental","pubTime":"2024-09-18 21:24","pubTimestamp":1726665889,"startTime":"0","endTime":"0","summary":"Sept 18 (Reuters) - BioCardia Inc   :   * BIOCARDIA REGAINS FULL COMPLIANCE WITH NASDAQ LISTING REQUIREMENTSSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","IE00BKPKM429.USD","NDAQ","NQmain","SQQQ","PSQ","BK4588","MNQmain","QID","LU2095319765.USD","QLD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU2210150020.SGD","TQQQ","IE00B3QW5Z07.USD","BK4112","LU2210149790.SGD","BK4585",".IXIC","BK4139"],"gpt_icon":0},{"id":"2468958548","title":"BioCardia regains compliance with Nasdaq Capital Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2468958548","media":"seekingalpha","labels":["Policy And Regulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468958548?lang=en_us&edition=fundamental","pubTime":"2024-09-18 20:35","pubTimestamp":1726662955,"startTime":"0","endTime":"0","summary":"BioCardia (NASDAQ:BCDA) said the company has regained full compliance with the Nasdaq Capital Market’s listing requirements.\nPress Release","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4150614-biocardia-regains-compliance-with-nasdaq-capital-market","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Policy And Regulatory","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["MNQmain","LU2095319765.USD","TQQQ","PSQ","IE00BGHQF748.EUR","IE00BKPKM429.USD","BCDA",".IXIC","NQmain","BK4588","QID","BK4585","IE00B64PRP62.GBP","SQQQ","LU2210149790.SGD","BK4112","IE00B3QW5Z07.USD","LU2210150020.SGD","QLD","BK4139","NDAQ"],"gpt_icon":0},{"id":"2468583400","title":"BioCardia Regains Full Compliance With Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2468583400","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468583400?lang=en_us&edition=fundamental","pubTime":"2024-09-18 20:30","pubTimestamp":1726662601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240918:nTUA8WZNHX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2468758373","title":"BioCardia Regains Full Compliance with Nasdaq Listing Requirements","url":"https://stock-news.laohu8.com/highlight/detail?id=2468758373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2468758373?lang=en_us&edition=fundamental","pubTime":"2024-09-18 20:30","pubTimestamp":1726662600,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Sept.  18, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/18/2948196/0/en/BioCardia-Regains-Full-Compliance-with-Nasdaq-Listing-Requirements.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2210149790.SGD","BK4585","BCDA","BK4112","IE00BGHQF748.EUR","LU2095319765.USD","BK4139","BK4588","LU2210150020.SGD","IE00B64PRP62.GBP",".IXIC","IE00BKPKM429.USD","NDAQ","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2467002333","title":"Wall Street Breakfast: The Week Ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2467002333","media":"seekingalpha","labels":["Economic Data","analysis"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2467002333?lang=en_us&edition=fundamental","pubTime":"2024-09-15 18:19","pubTimestamp":1726395564,"startTime":"0","endTime":"0","summary":"Legacy automakers scramble to counter 'existential threat' from nimble Chinese EV makersBest stock ideas going into the elections15 ‘Vintage Values’ names for 2025Try a barbell of Magnificent 7 and midcap techPalantir Chairman Thiel has filed to sell up to $1B in stock16 new GLP-1 weight-loss drugs could be launched by 202950 stocks that face tax-loss selling pressureLithium shares surge as world's biggest EV battery maker cuts output at major mine","market":"sh","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212395636/image_1212395636.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1212395636/image_1212395636.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4721183-wall-street-breakfast-week-ahead","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Economic Data,analysis","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["ELTP","US12M.BOND","FERG","DKS","BCDA","DJT","LU0477156953.USD","IRM","DRI","BK4590","LEN","IE00BFSS8Q28.SGD","IE00B3SWFQ91.USD","IE00BJTD4N35.SGD","VTR","VTLE","FDX","ASTS","SCS","US2Y.BOND","IE00BVYPNV92.GBP","IE00BHPRN162.USD","LU1721427968.SGD","FDS","IE00BJTD4V19.USD","US912797GW17.BOND","LU0052756011.USD","SBUX","US6M.BOND","CYBN","LU0109392836.USD","LU0072461881.USD","US5Y.BOND","IE0002270589.USD","LU0097036916.USD","AIG","IE00B19Z8X17.USD","IE00BDRTCR15.USD","IE00B5949003.HKD","AVGO","MSFT","US30Y.BOND","US912797HE00.BOND","US10Y.BOND","US7Y.BOND","IEP","US3Y.BOND","GIS"],"gpt_icon":1},{"id":"2466146324","title":"BRIEF-Biocardia Announces Closing Of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2466146324","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466146324?lang=en_us&edition=fundamental","pubTime":"2024-09-10 05:23","pubTimestamp":1725917038,"startTime":"0","endTime":"0","summary":"BioCardia Inc   :   * BIOCARDIA ANNOUNCES CLOSING OF UPSIZED $7.2 MILLION PUBLIC OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULESSource text for Eikon:    Further company coverage:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","PSQ","BK4139","NQmain","SQQQ","BK4585","IE00BKPKM429.USD","NDAQ","MNQmain","QID","LU2210149790.SGD","IE00B3QW5Z07.USD","IE00B64PRP62.GBP","TQQQ","QLD","LU2210150020.SGD","BK4112","LU2095319765.USD",".IXIC","BCDA","BK4588"],"gpt_icon":1},{"id":"2466611705","title":"BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2466611705","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466611705?lang=en_us&edition=fundamental","pubTime":"2024-09-10 04:05","pubTimestamp":1725912300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240909:nTUA4PB9RJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2466103371","title":"BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2466103371","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2466103371?lang=en_us&edition=fundamental","pubTime":"2024-09-10 04:05","pubTimestamp":1725912300,"startTime":"0","endTime":"0","summary":"SUNNYVALE, Calif., Sept.  09, 2024  (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary dise","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/09/09/2943208/0/en/BioCardia-Announces-Closing-of-Upsized-7-2-Million-Public-Offering-Priced-At-The-Market-Under-Nasdaq-Rules.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","BK4585","IE00B64PRP62.GBP","PSQ","TQQQ","BCDA","IE00B3QW5Z07.USD","SQQQ",".IXIC","LU2095319765.USD","QLD","LU2210150020.SGD","NQmain","QID","BK4139","MNQmain","LU2210149790.SGD","BK4588","NDAQ","IE00BKPKM429.USD","IE00BGHQF748.EUR"],"gpt_icon":1},{"id":"2463763250","title":"BUZZ-BioCardia drops as co raises equity after Thursday's surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2463763250","media":"Reuters","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463763250?lang=en_us&edition=fundamental","pubTime":"2024-08-30 23:59","pubTimestamp":1725033572,"startTime":"0","endTime":"0","summary":"** BioCardia Inc's    shares down 11.7% at $3.55 on Fri after co capitalizes on big pop in its stock to raise equity   ** Cell therapy provider's shares on Thurs closed up ~83% at $4.02, a day after US FDA cleared its heart device, called Morph DNA Steerable Introducer   ** Co early Fri announced pricing public offering of 2.4 mln shares and warrants to buy up to 2.4 mln shares at $3 for $7.2 mln gross proceeds   ** Management and directors, institutional investors, certain existing investors participated in offering, co said   ** 5-yr warrants have exercise price of $3, and exercisable immediately   ** Co, which has ~2.1 mln shares outstanding, plans to use net proceeds for working capital, general purposes   ** With move on the session, stock down 64% in 2024 and well off 1-yr closing high of $16.05 hit in Nov ","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139"],"gpt_icon":1},{"id":"2463381756","title":"BioCardia Shares Drop 10% After Public Offering Prices","url":"https://stock-news.laohu8.com/highlight/detail?id=2463381756","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463381756?lang=en_us&edition=fundamental","pubTime":"2024-08-30 21:55","pubTimestamp":1725026100,"startTime":"0","endTime":"0","summary":"BioCardia shares were down 10% to $3.61 after the company priced a public offering, which includes participation from management and directors, institutional investors and certain existing investors.The therapeutic treatment company said the offering is for the purchase and sale of 2.4 million shares and warrants to buy up to 2.4 million shares at a combined offering price of $3 a share and accompanying warrant.The California-based company expects to receive proceeds of $7.2 million, before deducting placement agent fees and other offering expenses.The warrants will have an exercise price of $3 a share, will be exercisable immediately and will expire five years from the issuance date.The closing of the offering is expected to occur Tuesday. BioCardia intends to use the proceeds from the offering for working capital and general corporate purposes.The stock hit its 52-week low of $1.96 Wednesday, but jumped 83% Thursday after the Food and Drug Administration cleared BioCardia to market t","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCDA"],"gpt_icon":1},{"id":"2463737815","title":"BioCardia Prices $7.2 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2463737815","media":"MT Newswires Live","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463737815?lang=en_us&edition=fundamental","pubTime":"2024-08-30 20:49","pubTimestamp":1725022141,"startTime":"0","endTime":"0","summary":"BioCardia  said Friday it is making a public offering of 2.4 million shares for $3.00 apiece or a total of $7.2 million in gross proceeds.The offering, which is expected to close on Tuesday, includes warrants to purchase up to another 2.4 million shares and each warrant has an exercise price of $3.00 per warrant, BioCardia said.Shares of the company were down 3.5% in recent Friday premarket activity.Price: 3.8800, Change: -0.14, Percent Change: -3.48","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCDA","BK4139"],"gpt_icon":1},{"id":"2463393277","title":"BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced at-the-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2463393277","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463393277?lang=en_us&edition=fundamental","pubTime":"2024-08-30 20:00","pubTimestamp":1725019201,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240830:nTUA8YJPFM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BCDA"],"gpt_icon":0},{"id":"2463739808","title":"Press Release: BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2463739808","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463739808?lang=en_us&edition=fundamental","pubTime":"2024-08-30 20:00","pubTimestamp":1725019200,"startTime":"0","endTime":"0","summary":"BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules. SUNNYVALE, Calif., Aug. 30, 2024  -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the pricing of its upsized public offering with participation from management and directors, institutional investors, and certain existing investors of the Company for the purchase and sale of 2,400,000 shares of common stock  and warrants to purchase up to 2,400,000 shares of common stock at a combined offering price of $3.00 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The company expects to receive aggregate gross proceeds of $7.2 million, before deducting placement agent fees and other offering expenses. The warrants will have an exercise price of $3.00 per share, will be exercisable immediately and will expire five years from the issuance date","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2095319765.USD","R","BK4588","LU2210149790.SGD","NQmain","NDAQ","LU2210150020.SGD",".IXIC","TM","BK4139","BCDA","IE00BKPKM429.USD","BK4555","BK4022","BK4585","03160","BK4232","BK4099","BK4112"],"gpt_icon":1},{"id":"2463025410","title":"Dow Jumps Over 100 Points; Nvidia Earnings Top Views","url":"https://stock-news.laohu8.com/highlight/detail?id=2463025410","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463025410?lang=en_us&edition=fundamental","pubTime":"2024-08-29 22:00","pubTimestamp":1724940051,"startTime":"0","endTime":"0","summary":" ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/08/40626551/dow-jumps-over-100-points-nvidia-earnings-top-views","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LUCY","NVDA","XRTX","PCOM","BCDA","BIG","ENSC","AILE"],"gpt_icon":1},{"id":"2463604259","title":"BioCardia Shares up 88% After FDA Clears Co's Device Used in Heart Procedures","url":"https://stock-news.laohu8.com/highlight/detail?id=2463604259","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463604259?lang=en_us&edition=fundamental","pubTime":"2024-08-29 21:34","pubTimestamp":1724938458,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20240829:nFWN3KG1IM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BCDA","BK4139"],"gpt_icon":0},{"id":"2463234255","title":"Sector Update: Health Care Stocks Advance Premarket Thursday","url":"https://stock-news.laohu8.com/highlight/detail?id=2463234255","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463234255?lang=en_us&edition=fundamental","pubTime":"2024-08-29 21:10","pubTimestamp":1724937023,"startTime":"0","endTime":"0","summary":"Health care stocks were advancing premarket Thursday with the Health Care Select Sector SPDR Fund  0.4% higher and the iShares Biotechnology ETF  also up 0.4%.Cooper  shares rose past 6% after it reported higher fiscal Q3 non-GAAP earnings and net sales. The company also raised its guidance for fiscal 2024 non-GAAP earnings per share.BioCardia  shares rallied by 95% after saying the US Food and Drug Administration cleared the company to market its Morph DNA Steerable Introducer product family.Catalent  shares were up more than 1% after it reported higher fiscal Q4 adjusted earnings and net revenue.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4530","GB00BDT5M118.USD","LU2272731782.SGD","LU2211815571.USD","BCDA","BK4007","BK4581","COO","BK4198","BK4585","LU1992135472.HKD","BK7016","BK4588","BK4139","XLV","IBB","COO.AU","LU1992135399.USD","LU2272731600.USD","CTLT"],"gpt_icon":0},{"id":"2463255236","title":"Traders Digest Nvidia Earnings, Upward Revision in Q2 Growth Data as US Equity Futures Rise Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2463255236","media":"MT Newswires Live","labels":["Economic Data"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463255236?lang=en_us&edition=fundamental","pubTime":"2024-08-29 21:09","pubTimestamp":1724936988,"startTime":"0","endTime":"0","summary":"US equity futures rose ahead of Thursday's opening bell as traders digested quarterly earnings from chipmaker Nvidia (NVDA) and a batch of economic data.Dow Jones Industrial Average futures rose 0.7%,","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Economic Data","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["DG",".SPX","BCDA","NVDA",".IXIC","EQR","PSTG",".DJI"],"gpt_icon":1},{"id":"2463256175","title":"BioCardia shares climb as it gets FDA clearance for its Morph DNA product family","url":"https://stock-news.laohu8.com/highlight/detail?id=2463256175","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463256175?lang=en_us&edition=fundamental","pubTime":"2024-08-29 21:07","pubTimestamp":1724936868,"startTime":"0","endTime":"0","summary":"Cellular therapeutics company BioCardia  said on Thursday that the Food and Drug Administration has cleared the company to market its Morph DNA Steerable Introducer product family. The clearance covers sixteen products in lengths of 30, 45, 71, and 90 centimeters in 5, 6, 7, and 8 French introducer sheath equivalent diameters.  These products are expected to cover clinical applications in interventional cardiology, radiology, and vascular surgery. “We estimate that more than a million procedures performed per year in the United States may benefit from these products, which are expected to have a list price starting at $1,000,” Peter Altman, BioCardia  CEO said. BioCardia  shares were up 96.8% in pre-market trading on Thursday.","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359314170/image_1359314170.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359314170/image_1359314170.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4145070-biocardia-shares-climb-as-it-gets-fda-clearance-for-its-morph-dna-product-family","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4139","BK4109","BCDA","DNA"],"gpt_icon":0},{"id":"2463258757","title":"BUZZ-BioCardia surges as US FDA clears heart device","url":"https://stock-news.laohu8.com/highlight/detail?id=2463258757","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2463258757?lang=en_us&edition=fundamental","pubTime":"2024-08-29 20:50","pubTimestamp":1724935816,"startTime":"0","endTime":"0","summary":"** Shares of cell therapy developer BioCardia    more than doubles to $4.42 premarket     ** Company says the U.S. FDA has cleared its device used in heart procedures    ** The device, called a Morph DNA Steerable Introducer, is designed to provide a pathway to introduce medical instruments such as catheters into the heart - BCDA    ** The clearance covers 16 products in the category of devices - BCDA   ** If gains hold, stock set to erase YTD losses of ~78%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDA","BK4139","BUZZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.biocardia.com","stockEarnings":[{"period":"1week","weight":-0.0738},{"period":"1month","weight":0.122},{"period":"3month","weight":-0.0707},{"period":"6month","weight":-0.5479},{"period":"1year","weight":-0.5658},{"period":"ytd","weight":-0.723}],"compareEarnings":[{"period":"1week","weight":0.0023},{"period":"1month","weight":0.0191},{"period":"3month","weight":0.0516},{"period":"6month","weight":0.0941},{"period":"1year","weight":0.3433},{"period":"ytd","weight":0.2041}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioCardia, Inc., a clinical-stage regenerative medicine company, engages in development of cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP, an autologous mononuclear cell therapy system for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary disease. The company is also developing allogeneic cells therapeutic platform, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic heart failure. In addition, it offers the Helix biotherapeutic delivery system that delivers therapeutics into the heart muscle with a penetrating helical needle from within the heart; and Morph deflectable guides and sheaths. The company is based in Sunnyvale, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.06938},{"month":2,"riseRate":0.5,"avgChangeRate":-0.000116},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.063445},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.020094},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.051537},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.041157},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.032675},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.106569},{"month":9,"riseRate":0.285714,"avgChangeRate":0.042817},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.037787},{"month":11,"riseRate":0.5,"avgChangeRate":0.054404},{"month":12,"riseRate":0.5,"avgChangeRate":0.01405}],"exchange":"NASDAQ","name":"BioCardia","nameEN":"BioCardia"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.28.1","shortVersion":"4.28.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioCardia,BCDA,BioCardia股票,BioCardia股票老虎,BioCardia股票老虎国际,BioCardia行情,BioCardia股票行情,BioCardia股价,BioCardia股市,BioCardia股票价格,BioCardia股票交易,BioCardia股票购买,BioCardia股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioCardia(BCDA),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioCardia(BCDA) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction